Angiotensin II receptor antagonists

Lancet

Volumn 355, Issue 9204, 2000, Pages 637-645

  Burnier, M ^a   Brunner, H R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; AMLODIPINE; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; COZAAR PLUS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INDOMETACIN; IRBESARTAN; KENZEN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; SARALASIN; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALSARTAN; VASODILATOR AGENT; WARFARIN;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD DRUG INTERACTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034685168     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)10365-9     Document Type: Review

References (104)

1. 8-angiotensin II for understanding and treatment of high blood pressure. Lancet. ii:1973;1045-1048.
2. Brunner H.R., Gavras H., Laragh J.H. Specific inhibition of the renin angiotensin system, a key for understanding blood pressure regulation. Prog Cardiovasc Dis. 17:1974;87-98.
3. Gavras H., Flessas A., Ryan T.J., Brunner H.R., Faxon D.P., Gavras I. Angiotensin II inhibition: treatment of congestive cardiac failure in a high-renin hypertension. JAMA. 238:1977;880-892.
4. effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 316:1987;1429-1435.
5. Lassie B.M. 15 years of heart-failure trials: what have we learned? Lancet. 352:1998;29-33. (suppl I).
6. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. the effect of angiotensin-converting-enzyme on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
7. MacKenzie H.S., Brenner B.M. Current strategies for retarding the progression of renal disease. Am J Kidney Dis. 31:1998;161-170.
8. Corvol P., Chauveau D., Jeanemaître X., Ménard J. Human renin inhibitor peptides. Hypertension. 16:1990;1-11.
9. Nussbeger J., Waeber B., Brunner H.R. Clinical pharmacology of ACE inhibition. Cardiology. 76:1989;11-22. (suppl 2).
10. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostini A. Plasma bradykinin in angio-oedema. Lancet. 351:1998;1693-1697.
11. Smith R.D., Timmermans P.B.M.W.M. Human angiotensin receptor subtypes. Curr Opin Nephrol Hypertens. 3:1994;112-122.
12. Bergsma D.J., Ellis C., Kumar C.et al. Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun. 183:1992;989-995.
13. Mukoyama M., Nakajima M., Horiuchi M., Sasamura H., Pratt R.E., Dzau V.J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem. 68:1993;24539-24542.
14. Timmermans P.B.M.W.M., Wong P.C., Chiu A.T.et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-251.
15. Ohkubo N., Matsubara H., Nozawa Y.et al. Angiotensin type 2 receptors are re-expressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation. 96:1997;3954-3962.
16. Stoll M., Steckelings M., Paul M., Bottari S.P., Metzger R., Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 95:1995;651-657.
17. 2 receptor inhibits proliferation and promotes differentition in PC12W cells. Mol Cell Endocrinol. 122:1996;59-67.
18. Li J.S., Touyz R.M., Schiffrin E.L. Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension. 31:1998;487-492.
19. Cao Z., Dean R., Wu L., Casley D., Cooper M.E. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension. 34:1999;408-414.
20. Yerkes E., Nishimura H., Miyazaki Y., Tsuchida S., Brock J.W. 3rd., Ichikawa I. Role of angiotensin in the congenital anomalies of the kidney and urinary tract in the mouse and human. Kidney Int. 67:1998;75-77.
21. Pope J.C. 4th., Brock J.W. 3rd., Adams M.C., Stephens F.D., Ichikawa I. How they begin and how they end: classic and new theories for the development and deterioration of congenital anomalies of the kidney and urinary tract, CAKUT. J Am Soc Nephrol. 10:1999;2018-2028.
22. 1receptor-transfected Chinese hamster ovary cells. Eur J Pharmacol. 367:1999;413-422.
23. 1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol. 372:1999;199-206.
24. Goa K.L., Wagstaff A.J. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs. 51:1996;820-845.
25. Chiolero A., Burnier M. Pharmacology of valsartan, an angiotensin II receptor antagonist. Expert Opin Investig Drug. 7:1998;1915-1925.
26. Gillis J.C., Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs. 54:1997;885-902.
27. Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens. 11:1997;91-95. (suppl 2).
28. McClellan K.J., Markham A. Telmisartan. Drugs. 56:1998;1039-1044.
29. McClellan K.J., Balfour J.A. Eprosartan. Drugs. 55:1998;713-718.
30. Spinale F.G., DeGasparo M., Whitehead S.et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure I: effects on left ventricular performance and neurohormonal systems. Circulation. 96:1997;2385-2396.
31. Hayashi N., Fujimura Y., Yamamoto S.et al. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor profile. 4th communication: improvement of heart failure of rats with myocardial infarction by valsartan. Arzneim-Forsch/Drugs Res. 47:1997;625-629.
32. Mizuno K., Niimura S., Katoh K., Fukuchi S. TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats. Lif Sci. 54:1994;1987-1994.
33. MacKenzie H., Ots M., Ziai F.et al. Angiotensin receptor antagonists in experimental models of chronic renal failure. Kidney Int. 63:1997;140-143. (suppl).
34. Remuzzi A., Fassi A., Sangalli F.et al. Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism. Exp Nephrol. 6:1998;28-38.
35. Von Lutteroti N., Camargo M.J.F., Campbell W.G.et al. Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl-sensitive rats. J Hypertens. 10:1992;949-957.
36. Fornes P., Richer C., Vacher E., Bruneval P., Giudicelli J.F. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after withdrawal. J Cardiovasc Pharmacol. 22:1993;305-313.
37. Conlin P.R., Spence J.D., Williams B.et al. Angiotensin II antagonists for hypertension: are there differences in efficacy. Am J Hypertens. 2000;. (in press).
38. Reeves R.A., Lin C.S., Kassler-Taub K., Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension. 31:1998;1311-1316.
39. Munafo H., Christen Y., Nussberger J.et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 51:1992;513-521.
40. Muller P., Cohen T., De Gasparo M., Sioufi A., Racine-Poon A., Howald H. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol. 47:1994;231-245.
41. Ribstein J., Sissmann J., Picard A., Bouroudian M., Mimran A. Effect of the angiotensin II antagonist SR 47436 (BMS 18695) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens. 12:1994;131. (abstr) (suppl 3).
42. Delacretaz E., Nussberger J., Biollaz J., Waeber B., Brunner H.R. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension. 25:1995;14-21.
43. Gradman A.H., Arcuri K.E., Goldberg A.I., et al A. randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 25:1995;1345-1350.
44. Black H.R., Graff A., Shute D.et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Human Hypertens. 11:1997;483-489.
45. Mimran A., Ruilope L., Kerwin L.et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Human Hypertens. 12:1998;203-208.
46. Zanchetti A., Omboni S., DiBaggio C. Candesartan Cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Human Hypertens. 11:1997;57-59. (suppl 2).
47. Smith D.H.G., Neutel J.M., Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther. 15:1998;229-240.
48. Goldberg A.I., Dunlay M.C., Sweet C.S. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 75:1995;793-795.
49. Corea L., Cardoni O., Fogari R.et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharm Ther. 60:1996;341-346.
50. Stumpe K.O., Haworth D., Hoglund C.et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press. 7:1998;31-37.
51. Hegner G., Faust G., Freytag F., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol. 52:1997;173-177.
52. MacKay J.H., Arcuti K.E., Goldberg A.I., Snapinn S.M., Sweet C.S. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med. 156:1996;278-279.
53. Hall W.D., Montoro R., Littlejohn T., Jain A., Feliciano N., Zheng H. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin Drug Invest. 16:1998;203-210.
54. Plouin P.F. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide. J Human Hypertens. 11:1997;65-66. (suppl 2).
55. 1 receptor antagonists. Hypertension. 33:1999;850-855.
56. Hedner T., Oparil S., Rasmussen K.et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 12:1999;414-417.
57. Fogari R., Zoppi A., Mugellini A.et al. Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Curr Ther Res. 60:1999;195-206.
58. Andersson O.K., Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Pressure. 7:1998;53-59.
59. Lacourcière Y., Asmar R. Comparison of the effects of candesartan and losartan on ambulatory blood pressure in patients with essential ambulatory hypertension: a forced titration study. Am J Hypertens. 12:1999;41. (abstr).
60. Kassler-Taub K., Littlejohn T., Elliott W., Ruddy T., Adler E. for the Irbesartan/Losartan Study Investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens. 11:1998;445-453.
61. Oparil S., Guthrie R., Lewis A.J.et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers irbesartan and losartan. Clin Ther. 20:1998;398-409.
62. Mallion J.M., Siche J.P., Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Human Hypertens. 13:1999;657-664.
63. Mazzolai L., Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Safety. 21:1999;23-33.
64. Lacourcière Y., Brunner H.R., Irwing R.et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens. 12:1994;1387-1393.
65. Benz J., Oshrain C., Henry D., Avery C., Chaing Y., Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 37:1997;101-107.
66. Lacourcière Y. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Int J Clin Pract. 53:1999;99-103.
67. Acker G., Greenberg A. Angioedema induced by the angiotensin II blocker losartan. N Engl J Med. 333:1995;1572.
68. Van Rijnsoever E.W., Kwee-Zuiderwijk W.J., Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med. 158:1998;2063-2065.
69. McInnes G.T., O'Kane K.P.J., Jonker J., Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Human Hypertens. 11:1997;75-80. (suppl 2).
70. Toto R., Shultz P., Raij L.et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension. 31:1998;684-691.
71. Faulhaber H.D., Mann J.F.et al. Effect of valsartan on renal function in patients with hypertension and stable renal insufficiency. Curr Ther Res. 60:1999;170-183.
72. Saine D., Ahrens E. Renal impairment associated with losartan. Ann Intern Med. 124:1996;775.
73. Holm E.A., Randlov A., Strandgard S. Acute renal failure after losartan treatment in a patient with bilateral renal artery stenosis. Blood Press. 5:1996;360-362.
74. Missouris C.G., Ward D.E., Eastwood J.B., MacGregor G.A. Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney. Heart. 77:1997;391-392.
75. Ostermann M., Goldsmith D.J.A., Doyle T., Kingswood J.C., Sharpstone P. Reversible acute renal failure induced by losartan in a renal transplant recipient. Postgrad Med J. 73:1997;105-107.
76. Pitt B., Segal R., Martinez F.A.et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly study, ELITE). Lancet. 349:1997;747-752.
77. Julian B.A., Brantley R.R. Jr., Barker C.V.et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol. 9:1998;1104-1108.
78. Schwarzbeck A., Wittenmeier K.W., Hallfritzsch U. Anaemia in dialysis patients as a side-effect of sartans. Lancet. 352:1998;286.
79. Nakashima M., Uematsu T., Kosuge K., Kanamura M. Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 42:1992;333-335.
80. Burnier M., Roch-Ramel F., Brunner H.R. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 49:1996;1787-1790.
81. Soffer B.A., Wright J.T., Pratt H., Wiens B., Goldberg A.I., Sweet C.S. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 26:1995;112-117.
82. Theurmann P.A., Kenedi P., Schmidt A., Harder S., Rietbrock N. Influence of the angiotensin II antagonist losartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 98:1998;2037-2042.
83. Gottlieb S.S., Dickstein K., Fleck E.et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 8:1993;1602-1609. (part 1).
84. Dickstein K., Chang P., Willenheimer R., Haunso S., Remes J., Hall C., Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe heart failure. J Am Coll Cardiol. 26:1995;438-445.
85. Crozier I., Ikram H., Awan N.et al. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation. 91:1995;691-697.
86. Havranek E.P., Thomas I., Smith W.B.et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol. 33:1999;1174-1181.
87. Baruch L., Anand I., Cohen I.S., Ziesche S., Judd D., Cohn J.N. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to an angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation. 99:1999;2658-2664.
88. Burnier M., Hagman M., Nussberger J.et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension. 25:1995;602-609. (part 1).
89. Gansevoort R.T., DeZeeuw D., deJong P.E. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 45:1994;861-867.
90. 1 antagonist irbesartan vs enalapril in hypertensive patients. J Hypertens. 16:1998;385-393.
91. Fricker A., Nussberger J., Meilenbrock S., Brunner H.R., Burnier M. Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Kidney Int. 54:1998;2089-2097.
92. Remuzzi A., Perico N., Sangalli F.et al. ACE inhibition and Ang II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol. 276:1999;457-466.
93. Plum J., Buenten B., Nemeth R., Grabensee B. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol. 9:1998;2223-2234.
94. Ots M., MacKenzie H.S., Troy J.L., Rennke H.G., Brenner B.M. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol. 9:1998;224-230.
95. Hebert L.A., Falkenheim M.E., Nahman N.S., Cosio F.G., O'Dorisio T.M. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol. 19:1999;1-6.
96. Russo D., Pisani A., Balletta M.M.et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kid Dis. 33:1999;851-856.
97. Pitt B., Dickerstein K., Benedict C.et al. Combined treatment with losartan and enalapril vs enalapril on neurohormonal activation in patients with heart failure. Circulation 94: I-428. 1996.
98. McKelvie R.S., Yusuf S., Pericak D.et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation. 100:1999;1056-1064.
99. Hamroff G., Katz S.D., Mancini D.et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 99:1999;990-992.
100. DiPasquale P., Bucca V., Scalzo S., Paterna S. Safety, tolerability, and neurohormonal changes of the combination captopril plus losartan in the early post-infarction period: a pilot study. Cardiovasc Drugs Ther. 12:1998;211-216.
101. Dahlöf B., Devereux R., DeFaire U.et al. The Losartan Intervention For Endpoint Reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens. 10:1997;705-713.
102. Swedberg K., Pfeffer M., Granger C.et al. Candesartan in Heart Failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Cardiac Failure. 5:1999;276-282.
103. Dickstein K., Kjekhus J. Comparison of the effects of losartan and captopril on mortality in patients following acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol. 83:1999;477-481.
104. 1 receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J. 20:1999;997-1008.